about
CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV controlA human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques.Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controllerDirect interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.Use of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individualsPathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective.HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice.Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells.Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected.Gut Microbiota Linked to Sexual Preference and HIV Infection.Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV controlDefinition of the viral targets of protective HIV-1-specific T cell responsesLymphocyte Activation Dynamics Is Shaped by Hereditary Components at Chromosome Region 17q12-q21Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells.Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions.Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.Virological, immune and host genetics markers in the control of HIV infection.Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints.Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.Identification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for In Vivo HIV Control.A case of hyper-reactive malarial splenomegaly. The role of rapid antigen-detecting and PCR-based tests.Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix).A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors.Increased expression of SAMHD1 in a subset of HIV-1 elite controllers.Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain.A minimal T-cell immunogen designed to cover HIV-1 specificities associated with control is immunogenic in mice and breaks CTL immunodominance.Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection.DNA vaccines expressing conserved elements provide potent and broad immune responses.Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment.Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy In Vitro.Phase I clinical trial of an intranodally administered mRNA based therapeutic vaccine against HIV-1 infectionInfluenza, but not HIV-specific CTL epitopes, elicits delayed-type hypersensitivity (DTH) reactions in HIV-infected patientsDifferential prevalence of the HLA-C −35 CC genotype among viremic long term non-progressor and elite controller HIV+ individualsModulation of antibody secreting cells and neutralizing Ab activity in HIV infected individuals undergoing structured treatment interruptions
P50
Q28740354-3373B0E6-3B2D-4D6C-A7C9-4A6C56F5613FQ30934059-A8AFDA56-D4DE-485A-A0B8-C8B3DD691EBEQ31148797-A4605479-B42F-473C-AFB3-63E430C88C74Q33589386-6073813F-3C1E-40B9-B543-879B7C3DF4A5Q34182086-8A5A5367-EECF-4207-AFBA-D51F5086E60CQ34594624-1656FD79-6B6F-4BA1-B3E0-363F46E0DEABQ34630184-635E663D-00FC-4603-B1FD-9E6A97BF5798Q34650866-A2E1C4C3-F8E4-4AD2-A8AB-EB9B79B84A9BQ34653619-65BD57E4-A2D9-4C0A-B8C9-506B0515B600Q34663141-C0146E4B-4B81-4816-B1FA-E1C59F741328Q34664829-A1200FE7-708E-4300-AB14-C77FFE6A3FEDQ34676893-7F712D26-9A70-4604-8A6A-1C29FED1655AQ35130519-E13B752F-F721-47C0-A82D-0BC5BAA7D1DFQ35192655-473B5A2D-EAB7-459B-9092-0A5ABBB928F6Q35800157-0DEC50F1-30B9-4251-A4D1-D647B24886EAQ36189902-75DFCB8D-1F60-41CA-ABDC-A58ECCFC9682Q36533322-157423FC-1206-4782-85EA-4F55ED641597Q36707546-A97BA8BE-8195-464D-BEBD-96D30CB3FCC6Q37521828-690FE04C-09B3-4D09-90EC-681FF6FEF43DQ37628362-F0884E2F-1332-4A37-B543-211AF6EA0993Q37714013-4F431561-BCA7-49B4-B45E-34EFFFEB0C0DQ38415577-71AF24A9-6929-43C9-A9FD-7E2BFAE892C6Q38737586-6875DED4-A01E-4918-8A1D-6AE1ED11803DQ39274475-727C0399-9719-4B0E-ADF5-ED57B3CF9BBEQ40525829-3106A504-C343-4E50-83EB-EC28170BACC4Q40919787-377D1050-6257-4A91-AD9E-DE3676122D9BQ41929341-7A7D1BDB-C012-457A-A4B6-1F0C332AF385Q42165676-A08D0AF4-7F5A-4EE8-BFEE-555FDA990328Q42203657-212CB691-46A0-4040-8408-8689E219DCFFQ43102288-1F17B957-5318-49D0-8878-73A3A275A66BQ43237663-BB7BF2D1-E2B9-457B-9DAD-E6E8E0479E00Q45795062-5DBD7690-0E22-40AC-A4C2-07265BA0B044Q46500540-0B7B6CEF-26B6-4E65-971A-4BD5B956691FQ46986492-679662F1-CFE2-4522-90F5-59FB7D38591BQ48673677-3529EF04-9B8C-4F50-A31A-3298CDE7855EQ50334467-A0D24E89-52E9-43E4-B341-65D0E8FD838CQ57023723-90A7E999-024B-46BE-ADE4-D2C80D099945Q57259554-8E577497-53CE-49E5-9F7D-B99FE1971EB7Q57259559-831BC2FA-17B1-4808-B75D-0D8E99471947Q57259566-B068F89F-965E-40EE-9F65-64D5AC993442
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Beatriz Mothe
@ast
Beatriz Mothe
@en
Beatriz Mothe
@es
Beatriz Mothe
@nl
type
label
Beatriz Mothe
@ast
Beatriz Mothe
@en
Beatriz Mothe
@es
Beatriz Mothe
@nl
prefLabel
Beatriz Mothe
@ast
Beatriz Mothe
@en
Beatriz Mothe
@es
Beatriz Mothe
@nl
P106
P21
P31
P496
0000-0001-9975-407X